[go: up one dir, main page]

NO986024D0 - Substituerte 3,5-difenyl-1,2,4-triazoler og deres anvendelse som farmas÷yti - Google Patents

Substituerte 3,5-difenyl-1,2,4-triazoler og deres anvendelse som farmas÷yti

Info

Publication number
NO986024D0
NO986024D0 NO986024A NO986024A NO986024D0 NO 986024 D0 NO986024 D0 NO 986024D0 NO 986024 A NO986024 A NO 986024A NO 986024 A NO986024 A NO 986024A NO 986024 D0 NO986024 D0 NO 986024D0
Authority
NO
Norway
Prior art keywords
triazoles
diphenyl
pharmaceutical
substituted
Prior art date
Application number
NO986024A
Other languages
English (en)
Other versions
NO317180B1 (no
NO986024L (no
Inventor
Renu Lattmann
Pierre Acklin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4214048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO986024(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO986024D0 publication Critical patent/NO986024D0/no
Publication of NO986024L publication Critical patent/NO986024L/no
Publication of NO317180B1 publication Critical patent/NO317180B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO19986024A 1996-06-25 1998-12-21 Substituerte 3,5-difenyl-1,2,4-triazoler og deres anvendelse som farmasoytiske metallchelatorer NO317180B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH159396 1996-06-25
PCT/EP1997/003315 WO1997049395A1 (en) 1996-06-25 1997-06-24 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators

Publications (3)

Publication Number Publication Date
NO986024D0 true NO986024D0 (no) 1998-12-21
NO986024L NO986024L (no) 1998-12-21
NO317180B1 NO317180B1 (no) 2004-09-06

Family

ID=4214048

Family Applications (3)

Application Number Title Priority Date Filing Date
NO19986024A NO317180B1 (no) 1996-06-25 1998-12-21 Substituerte 3,5-difenyl-1,2,4-triazoler og deres anvendelse som farmasoytiske metallchelatorer
NO2006017C NO2006017I2 (no) 1996-06-25 2006-11-30 4-[3,5-bis(2-hydroksifenyl)-[1,2,4]triazol-l-yl]benzosyre(Deferasirox)
NO2018014C NO2018014I2 (no) 1996-06-25 2018-04-17 Deferasirox eller et farmasøytisk akseptabelt salt derav

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO2006017C NO2006017I2 (no) 1996-06-25 2006-11-30 4-[3,5-bis(2-hydroksifenyl)-[1,2,4]triazol-l-yl]benzosyre(Deferasirox)
NO2018014C NO2018014I2 (no) 1996-06-25 2018-04-17 Deferasirox eller et farmasøytisk akseptabelt salt derav

Country Status (36)

Country Link
US (3) US6465504B1 (no)
EP (1) EP0914118B1 (no)
JP (1) JP3541042B2 (no)
KR (1) KR100616378B1 (no)
CN (1) CN1146415C (no)
AP (1) AP1127A (no)
AR (1) AR007479A1 (no)
AT (1) ATE226435T1 (no)
AU (1) AU718037B2 (no)
BG (1) BG64248B1 (no)
BR (1) BR9709973A (no)
CA (1) CA2255951C (no)
CY (2) CY2429B1 (no)
CZ (1) CZ291470B6 (no)
DE (3) DE69716602T2 (no)
DK (1) DK0914118T3 (no)
ES (1) ES2187785T3 (no)
FR (1) FR06C0049I2 (no)
GE (1) GEP20084355B (no)
HU (1) HU226232B1 (no)
IL (1) IL127212A0 (no)
LT (1) LTC0914118I2 (no)
LU (1) LU91291I2 (no)
MY (1) MY129541A (no)
NL (1) NL300248I2 (no)
NO (3) NO317180B1 (no)
NZ (1) NZ333308A (no)
OA (1) OA10946A (no)
PL (1) PL194758B1 (no)
PT (1) PT914118E (no)
RU (1) RU2208010C2 (no)
SI (1) SI0914118T1 (no)
SK (1) SK284319B6 (no)
TR (1) TR199802693T2 (no)
TW (1) TW533205B (no)
WO (1) WO1997049395A1 (no)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677487B2 (en) 2001-08-30 2004-01-13 Pharmacia Corporation α-haloenamine reagents
GB0126618D0 (en) * 2001-11-06 2002-01-02 Novartis Ag Organic compounds
ES2192494B1 (es) * 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
US8829198B2 (en) * 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
GB0223978D0 (en) * 2002-10-15 2002-11-20 Novartis Ag Organic compound
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
US20050008699A1 (en) * 2003-07-11 2005-01-13 Fred Wehling Effervescent glucosamine composition
KR20060123739A (ko) * 2003-11-10 2006-12-04 머크 앤드 캄파니 인코포레이티드 나트륨 채널 차단제로서의 치환된 트리아졸
EP1696917A1 (en) * 2003-12-19 2006-09-06 Novartis AG COMBINATION OF (a) N-{5- [4-(4-METHYL-PIPERAZINO-METHYL) -BENZOYLAMIDO] -2METHYLPHENYL]-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND THE USE THEREOF
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
WO2005115379A2 (en) * 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US20080114001A1 (en) * 2005-01-28 2008-05-15 Manley Paul W Use of Pyrimidylaminobenzamides for the Treatment of Diseases that Respond to Modulation of Tie-2 Kinase Activity
JP2008530043A (ja) * 2005-02-10 2008-08-07 ノバルティス アクチエンゲゼルシャフト 薬剤処分の改善法
AU2006252718B2 (en) * 2005-05-31 2010-04-15 Novartis Ag Treatment of liver diseases in which iron plays a role in pathogenesis
US20080311194A1 (en) * 2005-10-19 2008-12-18 Florian Battung Dispersible Tablets Comprising Deferasirox
WO2007051773A1 (en) * 2005-11-01 2007-05-10 Novartis Ag Method of scintigraphy
CN101415691B (zh) * 2006-02-03 2011-12-14 大正制药株式会社 三唑衍生物
EP2026800A1 (en) * 2006-05-09 2009-02-25 Novartis AG Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
US20110105575A1 (en) * 2006-05-23 2011-05-05 Hanspeter Nick Method of treatment of hereditary hemochromatosis
CL2007002026A1 (es) 2006-07-13 2008-06-06 Los Angeles Biomed Res Inst Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica.
US20100004303A1 (en) * 2006-08-04 2010-01-07 Novartis Ag Treatment of endocrine dysfunction using iron chelators
RU2339625C2 (ru) * 2006-11-02 2008-11-27 Российский химико-технологический университет (РХТУ им. Д.И. Менделеева) ЗАМЕЩЕННЫЕ N-[ω-АЗОЛ-1-ИЛ)АЛКИЛ]БЕНЗОЛСУЛЬФАМИДЫ В КАЧЕСТВЕ СРЕДСТВ С АНТИАГРЕГАЦИОННОЙ АКТИВНОСТЬЮ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
KR20090085081A (ko) * 2006-11-29 2009-08-06 노파르티스 아게 데페라시록스 (ｉｃｌ６７０ａ)의 다형체 형태
EP1927591A1 (en) * 2006-11-29 2008-06-04 Novartis AG Polymorphic Forms of Deferasirox (ICL670)
US20080262060A1 (en) * 2007-01-29 2008-10-23 Toth Zoltan G Crystalline forms of Deferasirox
RU2009146126A (ru) * 2007-05-14 2011-06-20 Новартис АГ (CH) Применение хелаторов железа для лечения инфаркта миокарда
EP1994930A1 (en) * 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
US20090082412A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched deferasirox
EP2062572A1 (en) 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions
CZ301873B6 (cs) * 2008-01-30 2010-07-14 Farmak, A. S. Zpusob prípravy kyseliny 4-[3,5-bis(2-hydroxyfenyl)-[1,2,4]triazol-1-yl]benzoové
WO2009106824A2 (en) * 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
WO2009111611A2 (en) 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
US20110097413A1 (en) * 2008-04-21 2011-04-28 Actavis Group Ptc Ehf Solid state forms of deferasirox salts and process for the preparation thereof
US20110171138A1 (en) * 2008-06-02 2011-07-14 Actavis Group Ptc Ehf Substantially pure deferasirox and processes for the preparation thereof
JPWO2010032489A1 (ja) 2008-09-22 2012-02-09 国立大学法人旭川医科大学 鉄キレート剤及びその製造方法、並びに鉄イオンの定量・捕捉方法
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
WO2010092419A1 (en) 2009-02-12 2010-08-19 Assistance Publique - Hopitaux De Paris Combined treatment of multiple sclerosis
US20120093828A1 (en) 2009-03-19 2012-04-19 Ibrahim Ashraf S Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
IT1398770B1 (it) * 2009-07-22 2013-03-18 Bellacchio Oligonucleotidi attivabili mediante l'appaiamento con sequenze di acidi nucleici e loro uso
WO2011021218A2 (en) * 2009-08-12 2011-02-24 Msn Laboratories Limited Process for the preparation of 4-[3,5-bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl]-benzoic acid and its amine salts
MX2012006434A (es) * 2009-12-07 2012-07-30 Mapi Pharma Ltd Procesos para la preparacion de deferasirox, y polimorfos de deferasirox.
US8703203B2 (en) 2010-07-08 2014-04-22 Ratiopharm Gmbh Oral dosage form of deferasirox
WO2012025935A2 (en) 2010-08-25 2012-03-01 Ramamohan Rao Davuluri A process for the preparation of 2-(2-hydroxyphenyl)-benz[1,3]oxazin-4-one and its use for preparation of 4-[3, 5-bis (2-hydroxyphenyl)-1h-1, 2, 4-triazol-1-yl] benzoic acid
MY165826A (en) * 2010-10-01 2018-05-17 Cipla Ltd Pharmaceutical composition
WO2012069946A1 (en) * 2010-11-24 2012-05-31 Alembic Pharmaceuticals Limited Process for the preparation of deferasirox
WO2012096183A1 (ja) 2011-01-14 2012-07-19 株式会社ダステック 高分子鉄キレート剤
WO2013053927A1 (en) 2011-10-14 2013-04-18 Photocure Asa Photodynamic diagnosis of abnormalities of the epithelial lining of the oesophagus with the means of a 5-ala ester
EP2779956A1 (en) 2011-10-14 2014-09-24 Photocure ASA Stent
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) * 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
EP2964659B1 (en) * 2013-03-06 2017-08-09 Biocon Limited Process for the preparation of deferasirox
MY170303A (en) 2013-03-08 2019-07-17 Novartis Ag Oral formulations of deferasirox
HK1215191A1 (zh) * 2013-05-10 2016-08-19 Cipla Limited 低剂量医药组合物
DE102013217390A1 (de) 2013-09-02 2015-03-05 Henkel Ag & Co. Kgaa Wasch- und Reinigungsmittel mit verbesserter Leistung
CN103454370B (zh) * 2013-09-11 2014-12-24 中美华世通生物医药科技（武汉）有限公司 一种利用hplc测定原料药中苯肼类化合物残留的方法
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
LT3116909T (lt) 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
TR201909052T4 (tr) 2014-05-20 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasiroks içeren suda dağılabilen tablet formülasyonu.
EP2987482A1 (en) 2014-08-22 2016-02-24 Santa Farma Ilaç Sanayi A.S. Soluble and dispersible pharamaceutical deferasirox formulation
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
JP6877339B2 (ja) 2014-10-14 2021-05-26 ノバルティス アーゲー Ｐｄ−ｌ１に対する抗体分子およびその使用
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
KR20160088965A (ko) 2015-01-16 2016-07-27 대원제약주식회사 데페라시록스를 함유하는 현탁제
JP6692826B2 (ja) 2015-03-10 2020-05-13 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
CN104817538A (zh) * 2015-03-13 2015-08-05 东南大学 去铁斯诺-他克林金属离子鳌合剂及其药物用途
WO2016167729A1 (en) 2015-04-16 2016-10-20 Öğün Yusuf Toktamiş Dispersible tablets comprising deferasirox
EP3095443A1 (en) 2015-05-21 2016-11-23 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Pharmaceutical composition comprising deferasirox
WO2016203488A1 (en) * 2015-06-16 2016-12-22 Havaldar Freddy H Preparation of novel deferasirox analogues for antimalarial activity
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
EP3964528A1 (en) 2015-07-29 2022-03-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
KR101695970B1 (ko) 2015-07-31 2017-01-13 건일제약 주식회사 데페라시록스 함유 산제 및 그 제조방법
CN106554770B (zh) * 2015-09-29 2018-10-19 杭州杜易科技有限公司 一种三唑衍生物金属离子荧光探针及其制备方法和应用
CA3002418C (en) 2015-10-23 2023-10-03 Vifor (International) Ag Novel ferroportin inhibitors
EP4424322A3 (en) 2015-12-17 2025-04-16 Novartis AG Antibody molecules to pd-1 and uses thereof
EP3429562A1 (en) 2016-03-17 2019-01-23 Lupin Limited Compositions of deferasirox
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018059922A1 (en) 2016-09-30 2018-04-05 Synthon B.V. Pharmaceutical composition comprising deferasirox
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CZ2017255A3 (cs) 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity
EP3489692A1 (de) 2017-11-28 2019-05-29 Siemens Healthcare Diagnostics Products GmbH Prothrombinzeit-reagenz enthaltend einen eisenchelator
TR201722910A2 (tr) 2017-12-29 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasi̇roks i̇çeren suda dağilabi̇len tablet formülasyonlari
KR20190110771A (ko) 2018-03-21 2019-10-01 주식회사 한국팜비오 데페라시록스를 함유하는 소형 분산성 정제
CN108727287B (zh) * 2018-05-10 2020-10-27 东南大学 1,2,4-三唑类化合物及其盐和应用
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
GR1009592B (el) * 2018-07-03 2019-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν χηλικο παραγοντα συμπλεκτικο του σιδηρου και μεθοδος για την παρασκευη αυτου
KR20200113116A (ko) 2019-03-22 2020-10-06 주식회사 한국팜비오 데페라시록스를 포함하는 필름코팅정제
TW202102478A (zh) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 新穎的鐵螯合物
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
IT202000000922A1 (it) 2020-01-20 2021-07-20 Cage Chemicals S R L Complessi di ferro e relativi sali come agenti di contrasto per MRI
US11155547B1 (en) * 2020-06-18 2021-10-26 Alterity Therapeutics Limited Compounds for and methods of treating diseases
WO2022186809A1 (en) 2021-03-05 2022-09-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi The film coated tablet comprising deferasirox
CN114276305B (zh) * 2021-12-28 2023-11-17 中山大学 一种三取代苯基-1,2,4-三氮唑衍生物及其制备和治疗神经元损伤的应用
CN114478410B (zh) * 2022-03-31 2022-11-29 中山大学 一种二取代苯基-1,2,4-三氮唑衍生物及其制备和应用
CN114591254B (zh) * 2022-03-31 2023-10-13 中山大学 一种3,5-二取代苯基-1,2,4-三氮唑衍生物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH388252A (de) 1963-01-24 1964-11-14 Geigy Ag J R Verfahren zum Schützen von Textilmaterial gegen Lichtschädigung
DE2628152C2 (de) 1976-06-23 1985-03-28 Bayer Ag, 5090 Leverkusen Fungizide und nematizide Mittel
US4528196A (en) * 1981-02-23 1985-07-09 The United States Of America As Represented By The Department Of Health And Human Services Chelating agents for the treatment of iron overload
SU1280851A1 (ru) * 1983-07-08 1996-05-27 Ростовский государственный университет 1-фенил-3-алкил-5-(o-оксифенил)-1,2,4-триазолы, обладающие транквилизирующим и антигипоксическим действием, и 1-фенил-3-н-бутил-5-(о-оксифенил)-1,2,4-триазол, обладающий транквилизирующим, антигипоксическим и анальгетическим действием
GB8429307D0 (en) 1984-11-20 1984-12-27 Shell Int Research Heterocyclic herbicides
IL84331A0 (en) * 1987-11-02 1988-04-29 Yissum Res Dev Co Pyridoxyl hydrazone derivatives and pharmaceutical compositions containing the same
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel

Also Published As

Publication number Publication date
NZ333308A (en) 2000-05-26
HK1020530A1 (en) 2000-05-12
AU3262997A (en) 1998-01-14
LTPA2007001I1 (lt) 2018-06-25
SI0914118T1 (en) 2003-04-30
AU718037B2 (en) 2000-04-06
NO2006017I1 (no) 2006-12-18
LU91291I2 (fr) 2007-01-29
NO2018014I2 (no) 2018-11-19
BG64248B1 (bg) 2004-07-30
US20030203954A1 (en) 2003-10-30
SK284319B6 (sk) 2005-01-03
MY129541A (en) 2007-04-30
CY2007005I2 (el) 2018-12-12
PL330119A1 (en) 1999-04-26
DE122007000020I1 (de) 2007-05-24
ES2187785T3 (es) 2003-06-16
EP0914118B1 (en) 2002-10-23
NL300248I2 (nl) 2007-03-01
BG103003A (en) 1999-09-30
WO1997049395A1 (en) 1997-12-31
TW533205B (en) 2003-05-21
NO2006017I2 (no) 2011-07-04
DE69716602T2 (de) 2003-06-26
HU226232B1 (en) 2008-07-28
US6596750B2 (en) 2003-07-22
LTC0914118I2 (lt) 2018-12-27
US20030069273A1 (en) 2003-04-10
CZ427298A3 (cs) 1999-03-17
CY2429B1 (en) 2004-11-12
KR20050098029A (ko) 2005-10-10
GEP20084355B (no) 2008-04-29
RU2208010C2 (ru) 2003-07-10
CN1146415C (zh) 2004-04-21
TR199802693T2 (xx) 1999-05-21
ATE226435T1 (de) 2002-11-15
HUP9903111A2 (hu) 2000-01-28
CA2255951C (en) 2006-10-10
OA10946A (en) 2003-02-27
AP9801407A0 (en) 1998-12-31
DE122007000020I2 (de) 2010-12-30
KR100616378B1 (ko) 2006-08-28
PL194758B1 (pl) 2007-07-31
US6465504B1 (en) 2002-10-15
CY2007005I1 (el) 2010-07-28
PT914118E (pt) 2003-02-28
CA2255951A1 (en) 1997-12-31
DK0914118T3 (da) 2003-02-24
EP0914118A1 (en) 1999-05-12
SK178598A3 (en) 1999-06-11
HUP9903111A3 (en) 2000-06-28
IL127212A0 (en) 1999-09-22
JP3541042B2 (ja) 2004-07-07
US6723742B2 (en) 2004-04-20
CZ291470B6 (cs) 2003-03-12
AP1127A (en) 2002-12-06
NL300248I1 (nl) 2007-02-01
BR9709973A (pt) 1999-08-10
JP2000507601A (ja) 2000-06-20
NO317180B1 (no) 2004-09-06
LU91291I9 (no) 2018-12-27
NO2018014I1 (no) 2018-04-17
NO986024L (no) 1998-12-21
FR06C0049I2 (fr) 2007-04-27
AR007479A1 (es) 1999-10-27
FR06C0049I1 (no) 2007-03-09
CN1223579A (zh) 1999-07-21
DE69716602D1 (de) 2002-11-28

Similar Documents

Publication Publication Date Title
NO986024D0 (no) Substituerte 3,5-difenyl-1,2,4-triazoler og deres anvendelse som farmas÷yti
NO991815D0 (no) Oksadiazoler, fremgangsmÕter for deres fremstilling og deres anvendelse som medikamenter
DK0906292T3 (da) Triazolylmercaptider og deres anvendelse som mikrobicider
NO993619D0 (no) Titandioksid, fremstilling og anvendelse derav
IS1989B (is) Kristallað form 4-[5-metýl-3-fenýlísoxasól-4-ýl] bensensúlfonamíðs
NO306401B1 (no) Oksazolidindionderivater, farmasöytisk preparat inneholdende slike derivater, og deres anvendelse
DK0832061T3 (da) Benzamidderivater og anvendelse deraf som vasopressin-antagonister
NO986023D0 (no) Vannbaserte farmas÷ytiske preparater
NO993003L (no) Sulfonamid-derivater, fremgangsmÕte for deres fremstilling og deres anvendelse som medikamenter
DK1019358T3 (da) 3,3-diarylpropylaminer, deres anvendelse og fremstilling
DK0770059T3 (da) Substituerede benzamidiner, deres fremstilling og deres anvendelse som lægemidler
NO962952L (no) 1,2,4-oksadiazolderivater og deres anvendelse som parasitticider for dyr
NO307510B1 (no) Bicykliske aromatiske forbindelser, deres anvendelse og farmasøytiske og kosmetiske preparater derav
DK0873308T3 (da) O-Carbamoyl-phenylalaninol-forbindelser og deres farmaceutisk anvendelige salte
NO962477D0 (no) Benzamidderivater, deres fremstilling og deres terapautiske anvendelse
DK0835254T3 (da) Oxazolidinonderivater, deres fremstilling og deres terapeutiske anvendelse
NO20001288L (no) Substituerte 1,2,3,4,5,6-heksahydro-2,6-metano-3-benzazocin- 10-oler, fremgangsmõte for fremstilling derav og anvendelse som legemiddel
NO954763D0 (no) Piperidinderivater, deres fremstilling og anvendelse
EE9800209A (et) Antiglükokortikoidne ravimaine
DK0811593T3 (da) 1,4-diaryl-2-flour-2-buten som insektcider og acaricider
NO308213B1 (no) Substituerte indanylidinacetylguanidiner, deres anvendelse og medikamenter inneholdende forbindelsene
NO980471L (no) Benzensulfonamidderivater, fremstilling derav og terapautiske anvendelser derav
NO20000066D0 (no) 6-pyrrolidin-2-ylpyrindin-derivater, deres fremstilling og deres farmasoeytiske anvendelse
DE69230590D1 (de) Mittel gegen fettleibigkeit
DE68906245D1 (de) Therapeutisches mittel gegen aids.

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: EXJADE; NAT. REG. NO/DATE: EU1063561-1 20060920; FIRST REG. NO/DATE: EU , EU/1/06/356/001-006 20060831

Spc suppl protection certif: 2006017

Filing date: 20061130

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: EXJADE; NAT. REG. NO/DATE: EU1063561-1 20060920; FIRST REG. NO/DATE: EU , EU/1/06/356/001-006 20060831

Spc suppl protection certif: 2006017

Filing date: 20061130

Extension date: 20210828

MK1K Patent expired
SPCK Change in the validity period of an spc

Free format text: PRODUCT NAME: DEFERASIROX ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV; THE CERTIFICATE IS VALID EVEN: 2021.08.31 (AMENDED IN ACCORDANCE WITH SECTION 84)

Spc suppl protection certif: 2006017

Filing date: 20061130

SPCE Application to extend a supplementary protection certificate (spc)

Free format text: PRODUCT NAME: DEFERASIROX ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV; NAT. REG. NO/DATE: NO , EU/1063561-1 20060828; FIRST REG. NO/DATE: EU , EU/1063561-1 20060920

Spc suppl protection certif: 2018014

Filing date: 20180417

SPCH Extension of a supplementary protection certificate (spc) granted

Free format text: PRODUCT NAME: DEFERASIROX ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV; NAT. REG. NO/DATE: NO , EU/1063561-1 20060828; FIRST REG. NO/DATE: EU , EU/1063561-1 20060920

Spc suppl protection certif: 2018014

Filing date: 20180417

Extension date: 20220228

SPCX Expiry of an spc

Free format text: PRODUCT NAME: DEFERASIROX OR A PHARMACEUTICAL ACCEPTABLE SALT HENCE

Spc suppl protection certif: 2006017

Effective date: 20210828

SPCX Expiry of an spc

Spc suppl protection certif: 2018014